SAN DIEGO, Sept. 25, 2015 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, provides its current revenue outlook for the second half
of 2015.
The Company is updating its revenue expectations for the second
half of the year to a range between $57
million and $61 million, bringing 2015 annual revenue
expectations to a range between $127 million
and $131 million.
Drivers for the updated expectations include increased
competition and price compression in the noninvasive prenatal
testing (NIPT) market.
"2015 has been and is a pivotal year for Sequenom. It is also a
year of transition," stated Dirk van den
Boom, Interim President and CEO of Sequenom.
"Importantly, we continue to make significant progress implementing
our strategy in reproductive health, including advancing our
in-network strategy, and improving our reach into the broader NIPT
market with new product launches. Within reproductive health,
I am particularly enthusiastic about our MaterniT™ GENOME
laboratory-developed test. This launch represents an exciting new
test that should allow for future growth in the NIPT market.
Moreover, we continue to make progress in oncology. We plan
on elucidating in greater detail both our reproductive health
business and our oncology opportunity at the September 28 Analyst Day. In parallel, we are
focused on increasing our organizational effectiveness, and
operational efficiency to ensure Sequenom's industry leadership
position."
The Company expects to announce its financial results for the
third quarter on November 4, 2015,
and will provide further discussion of its operating results at
that time.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and
services. The Company serves patients and physicians by
providing early patient management information. To learn how
Sequenom is interpreting the genome to improve your life, visit
www.sequenom.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the development of
innovative products and services, the anticipated revenue for
the second half of 2015, the ability to make significant progress
in implementing the Company's strategy, the ability to advance the
Company's in-network strategy and improve its reach into the
broader NIPT market, the potential for the launch of MaterniT
GENOME to provide future growth, the ability to make progress on
the Company's oncology development efforts and the ability to
increase organizational effectiveness and operational efficiency to
ensure Sequenom's leadership position and growth.
Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Risks are described more fully in the Company's filings with the
Securities and Exchange Commission, including without limitation
the Company's most recent Quarterly Report on Form 10-Q and other
documents subsequently filed with or furnished to the Securities
and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. The Company undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Logo -
http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-inc-updates-second-half-2015-revenue-outlook-300149068.html
SOURCE Sequenom, Inc.